within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01G_AminoglycosideAntibacterials.J01GB06_Amikacin;

model Amikacin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.88888888888889e-07,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.017,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.011,
    k12 = 1.5555555555555556e-06,
    k21 = 1.5555555555555556e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Amikacin</td></tr><tr><td>ATC code:</td><td>J01GB06</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>17</td><td>L</td></tr>
    <tr><td>clearance:</td><td>3.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Amikacin is an aminoglycoside antibiotic primarily used for the treatment of severe Gram-negative bacterial infections, including infections caused by multidrug-resistant organisms. It is usually reserved for hospital-acquired infections or when other antibiotics are ineffective. Amikacin is an approved drug and is included in the World Health Organization's List of Essential Medicines.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult subjects with normal renal function following single intravenous bolus dose administration.</p><h4>References</h4><ol><li><p>Severino, N, et al., &amp; Paredes, N (2023). Population pharmacokinetics of amikacin in suspected cases of neonatal sepsis. <i>British journal of clinical pharmacology</i> 89(7) 2254–2262. DOI:<a href=\"https://doi.org/10.1111/bcp.15697\">10.1111/bcp.15697</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36811146/\">https://pubmed.ncbi.nlm.nih.gov/36811146</a></p></li><li><p>Medellín-Garibay, SE, et al., &amp; García, B (2022). Amikacin pharmacokinetics in elderly patients with severe infections. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 175 106219–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2022.106219\">10.1016/j.ejps.2022.106219</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35618200/\">https://pubmed.ncbi.nlm.nih.gov/35618200</a></p></li><li><p>Bressolle, F, et al., &amp; Gomeni, R (1996). Population pharmacokinetics of amikacin in critically ill patients. <i>Antimicrobial agents and chemotherapy</i> 40(7) 1682–1689. DOI:<a href=\"https://doi.org/10.1128/AAC.40.7.1682\">10.1128/AAC.40.7.1682</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8807062/\">https://pubmed.ncbi.nlm.nih.gov/8807062</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01GB06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Amikacin;
